Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005

被引：0

作者：

Wisniewski, Mathilde ^{[1
]}

Placide, Pierre-Alain ^{[1
]}

Granier, Sandra ^{[1
]}

Al Shatti, Yacoub ^{[1
]}

Al Qalaf, Shuaib ^{[1
]}

Bouattour, Mohamed ^{[1
]}

Lamuraglia, Michele ^{[1
]}

Hammel, Pascal ^{[1
]}

机构：

[1] Univ Denis Diderot Paris VII, AP HP, Hop Beaujon, Dept Digest & Med Oncol, Clichy, France

来源：

HEPATOBILIARY SURGERY AND NUTRITION | 2018年 / 7卷 / 05期

关键词：

RANDOMIZED CONTROLLED-TRIAL; CANCER; CHEMORADIOTHERAPY; MULTICENTER;

D O I：

10.21037/hbsn.2018.08.03

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：399 / 402

页数：4

共 50 条

[41] A PHASE 2 ADJUVANT TRIAL OF GI-4000 PLUS GEMCITABINE VS. GEMCITABINE ALONE IN RAS+ PATIENTS WITH RESECTED PANCREAS CANCER: R1 SUBGROUP ANALYSIS
Richards, Donald
Muscarella, Peter
Bekaii-Saab, Tanios
Wilfong, Lalan
Rosemurgy, Alexander
Ross, Sharona
Raynov, Julian
Flynn, Patrick
Fisher, William
Whiting, Sam
Timcheva, Constanta
Harrell, Frank, Jr.
Mercaldo, Nathaniel
Kosten, Scott
Speyer, Sue
Richman, Joni
Coeshott, Claire
Cohn, Allen
Ferraro, John
Rodell, Timothy
Apelian, David
ANNALS OF ONCOLOGY, 2012, 23 : 5 - 5
[42] Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Oettle, Helmut
Neuhaus, Peter
Hochhaus, Andreas
Hartmann, Joerg Thomas
Gellert, Klaus
Ridwelski, Karsten
Niedergethmann, Marco
Zuelke, Carl
Fahlke, Joerg
Arning, Michael B.
Sinn, Marianne
Hinke, Axel
Riess, Hanno
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (14): : 1473 - 1481
[43] Randomized, cross-over phase III study of gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer - a multicenter trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO)
Boeck, S.
Vehling-Kaiser, U.
Waldschmidt, D.
Kettner, E.
Maerten, A.
Winkelmann, C.
Klein, S.
Kojouharoff, G.
Jung, A.
Heinemann, V
ONKOLOGIE, 2010, 33 : 25 - 25
[44] Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial
Alice C. Wei
Fang-Shu Ou
Qian Shi
Xiomara Carrero
Eileen M. O’Reilly
Jeffrey Meyerhardt
Robert A. Wolff
Hedy L. Kindler
Douglas B. Evans
Vikram Deshpande
Joseph Misdraji
Eric Tamm
Dushyant Sahani
Malcolm Moore
Elliot Newman
Nipun Merchant
Jordan Berlin
Laura W. Goff
Peter Pisters
Mitchell C. Posner
Annals of Surgical Oncology, 2019, 26 : 4489 - 4497
[45] Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma.
Safran, Howard
Winter, Kathryn A.
Abrams, Ross A.
Regine, William
Goodman, Karyn A.
Berger, Adam C.
Gillin, Michael
Philip, Agop Philip
Lowy, Andrew M.
Wu, Abraham Jing-Ching
DiPetrillo, Thomas A.
Corn, Benjamin W.
Seaward, Samantha A.
Haddock, Michael G.
Song, Suisui
Jiang, Yixing
Fisher, Barbara Jean
Katz, Alan W.
Mehta, Sharmila P.
Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[46] A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
Halfdanarson, Thorvardur R.
Foster, Nathan R.
Kim, George P.
Meyers, Jeffrey P.
Smyrk, Thomas C.
McCullough, Ann E.
Ames, Matthew M.
Jaffe, Jeffrry P.
Alberts, Steven R.
ONCOLOGIST, 2019, 24 (05): : 589 - +
[47] Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Scheithauer, Werner
Ramanathan, Ramesh K.
Moore, Malcolm
Macarulla, Teresa
Goldstein, David
Hammel, Pascal
Kunzmann, Volker
Liu, Helen
McGovern, Desmond
Romano, Alfredo
Von Hoff, Daniel D.
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (03) : 469 - +
[48] Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (Reprinted from vol 25, 1960, 2007)
Moore, Malcolm J.
Goldstein, David
Hamm, John
Figer, Arie
Hecht, Joel R.
Gallinger, Steven
Au, Heather J.
Murawa, Pawel
Walde, David
Wolff, Robert A.
Campos, Daniel
Lim, Robert
Ding, Keyue
Clark, Gary
Voskoglou-Nomikos, Theodora
Ptasynski, Mieke
Parulekar, Wendy
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4714 - 4720
[49] The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma : The TARGET study.
Watkins, D. J.
Starling, N.
Chau, I.
Thomas, J.
Webb, J.
Oates, J. R.
Brown, G.
Thomas, K.
Cunningham, D.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[50] randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
Tempero, Margaret A.
Reni, Michele
Riess, Hanno
Pelzer, Uwe
O'Reilly, Eileen Mary
Winter, Jordan Michael
Oh, Do-Youn
Li, Chung-Pin
Tortora, Giampaolo
Chang, Heung-Moon
Lopez, Charles D.
Tabernero, Josep
Van Cutsem, Eric
Philip, Philip Agop
Goldstein, David
Berlin, Jordan
Ferrara, Stefano
Li, Mingyu
Lu, Brian D.
Biankin, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →